NCT05554003View on ClinicalTrials.gov

Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Neuroendocrine TumorsFrailtyChemotherapy Effect
Interventions
DRUG

Temozolomide capsule

Metronomic temozolomide 60 mg/die continuously

Trial Locations (1)

20141

RECRUITING

European Institute of Oncology, IEO, IRCCS, Milan

All Listed Sponsors
lead

European Institute of Oncology

OTHER